Ophthalmoplegia Market Report 2025

The ophthalmoplegia market size has grown rapidly in recent years. It will grow from $1.68 billion in 2024 to $1.85 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth during the historic period can be attributed to the rising prevalence of neurological disorders, the expanding aging population, the growth of specialty clinics and hospitals, increasing demand for early diagnosis and treatment, a higher number of clinical trials, and greater healthcare insurance coverage.

The ophthalmoplegia market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth during the forecast period can be attributed to the rising prevalence of neurological disorders, an increasing aging population, growing awareness of eye movement disorders, higher healthcare expenditure, increased investment in healthcare by key players, and a growing patient population with diabetes and hypertension. Key trends during this period include advancements in diagnostic technologies, the development of novel therapeutic approaches, strategic collaborations and partnerships, technological innovations in eye tracking devices, and the development of muscle-strengthening drugs.

The increasing incidence of neurological disorders is expected to drive the growth of the ophthalmoplegia market. Neurological disorders affect the nervous system, including the brain, spinal cord, and nerves, leading to symptoms such as muscle weakness, coordination problems, and cognitive difficulties. The rising prevalence of these disorders is linked to genetic factors, which make individuals more vulnerable to conditions such as Alzheimer's and Parkinson's disease, as well as lifestyle changes such as poor diet, lack of physical activity, and chronic stress, all of which contribute to neurodegeneration and cognitive decline. Ophthalmoplegia plays a role in diagnosing neurological disorders such as Alzheimer's, multiple sclerosis, and stroke by identifying impaired eye muscle control, which indicates dysfunction in the nervous system. For example, in March 2023, the Alzheimer’s Association, a U.S.-based nonprofit organization, reported that 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections estimating this number to rise to 13.8 million by 2060. As a result, the increasing prevalence of neurological disorders is contributing to the growth of the ophthalmoplegia market.

The growth of the ophthalmoplegia market is also being fueled by the rising prevalence of autoimmune conditions. Autoimmune diseases occur when the immune system mistakenly attacks the body’s own healthy cells, leading to inflammation and tissue damage. These diseases are becoming more common due to genetic factors that make some individuals more prone to immune system dysfunction, combined with environmental triggers such as infections, stress, and lifestyle factors. Ophthalmoplegia can be particularly helpful in diagnosing autoimmune disorders, as it helps identify underlying immune system issues and allows for targeted treatments that address both the muscular paralysis and the autoimmune condition. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, 6,304,340 of the 73,241,305 insured individuals were diagnosed with at least one autoimmune disease, resulting in a prevalence rate of 8.61%. Consequently, the rising prevalence of autoimmune conditions is driving the growth of the ophthalmoplegia market.

The increasing number of head injuries or trauma cases is expected to further propel the ophthalmoplegia market. Head injuries or trauma refer to damage to the scalp, skull, or brain caused by external forces such as falls, accidents, or impacts. These injuries are becoming more common due to factors such as the rise in road accidents, with high-speed collisions, lack of helmet use, and reckless driving contributing to an increased risk of severe head injuries. Other factors such as workplace accidents, falls, sports injuries, and violence also contribute to the growing incidence of traumatic brain injuries. Ophthalmoplegia can help assess head injuries or trauma by detecting potential neurological damage through impaired eye movement, which allows for early diagnosis and intervention. For instance, in 2023, a report by the Wisconsin Department of Health Services, a U.S. government agency, showed a 3% increase in traumatic injuries caused by assault compared to 2022, with cases rising from 1,544 in 2022 to 1,584 in 2023. As such, the increasing cases of head injuries and trauma are driving the growth of the ophthalmoplegia market.

Major players in the ophthalmoplegia market are Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Medline Industries Inc., Regeneron Pharmaceuticals Inc., Carl Zeiss AG, Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Bayer AG, Santen Pharmaceutical Co. Ltd., Oculis Holding AG, Innovative Pharmaceuticals Pvt. Ltd., Clearside Biomedical Inc., Altacor Limited, Azura Ophthalmics Ltd., ViGeneron GmbH, Amritt Inc., GenSight Biologics SA, EyeBio Inc., Opthea Limited.

North America was the largest region in the ophthalmoplegia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ophthalmoplegia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ophthalmoplegia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ophthalmoplegia refers to the paralysis or weakness of one or more muscles responsible for eye movement. This condition can affect both voluntary and involuntary eye movements and may be caused by neurological disorders, muscle diseases, or vascular conditions.

The main types of ophthalmoplegia include external ophthalmoplegia and internuclear ophthalmoplegia. External ophthalmoplegia involves the paralysis or weakness of the extraocular muscles, leading to impaired eye movement and drooping eyelids. It is treated with surgery or drug therapy, and the treatments are utilized by end-users such as hospitals, clinics, and ambulatory care centers.

The ophthalmoplegia market research report is one of a series of new reports that provides ophthalmoplegia market statistics, including the ophthalmoplegia industry global market size, regional shares, competitors with the ophthalmoplegia market share, detailed ophthalmoplegia market segments, market trends, and opportunities, and any further data you may need to thrive in the ophthalmoplegia industry. This ophthalmoplegia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ophthalmoplegia market consists of revenues earned by entities by providing services such as diagnosis and imaging services, neurological and ophthalmic evaluations, genetic testing and counselling, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The ophthalmoplegia market also includes sales of eye patches and prisms, neuromuscular electrical stimulation (NMES) devices, corticosteroids, immunosuppressants, and botulinum toxin injections. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.